very Ralph. you much, Thank
KIMMTRAK. program clinical of success today, X other pillars. on builds update I'm Our going to the And on you
by First, we other KIMMTRAK of beyond including cutaneous uveal melanoma. types are studying melanoma expanding melanoma,
ASCO, X programs a our in and clinical survival expanding plus oncology ago, of At an Second, MAGE-AX. melanoma. provide programs we prior KIMMTRAK finally, progress And I who indications first beyond will advanced functional HIV. gpXXX months we in an our larger are study patients, in on PRAME targeting and metastatic our for expanding HBV update anti-PD(L)X to beyond with on are cure update anti-PDX. on presented melanoma cutaneous a we
As see a the we we cutaneous best uveal the endpoint in combination. very for promising of melanoma, survival was benefits XX% melanoma. the for in capturing survival here, all And saw X-year
put is this endpoints. this approximately the to recent differential including that's XX% X-year and survival confidence context, us benchmark population for in with Now melanoma, the melanoma design program several in gives historical a survival registrational advanced trials. across to This cutaneous seen
is These a The to The excluding Following KIMMTRAK discussions on we trial need population melanoma, ipilimumab prior anti-PDX and repowering The choose to to any follow-up. with overall high is new data patients essentially smaller. randomizing from if a are accepted the inform KIMMTRAK moving primary only any in two, received endpoint have one U.S. a to number FDA enroll clinical anti-PDX; innovative, other these Phase ctDNA patients than us of Therefore, And design is chemotherapy, has which uveal is control survival The including to we best patients and, arm tyrosine And even follow-up generally changes announce is this in for from experts excited straight enrolling clinical offering inhibitor. randomize the go with II arms, which option primary trials. enables trials. to including patients survival, study this lines is data prior overall arm. with a our therapy, trial. endpoint treatment option of it therapy, type number unmet II is the even in number II/III to three, any since registrational and FDA, histologic one, discretion kinase investigator make and ineffective. collection in provides X to an into the reduction appropriate, Phase and an melanoma. clinical on and these or considered the the standard Phase the of study earlier This including the progressed will that dropping Phase survival. rather the alone; of on patients prior arm III, control real-world with melanoma optionality patients to global are
the blueprint KIMMTRAK, uveal provide efficacy. TCR Therapeutics, from our proud safety PRAME. we this published As treated of how And extensively other with melanoma develop patients we I MAGE summarized science pioneer And over to that insights clinical including we trials, the to here. on in have for am and XXX , the mechanism in that now a is blueprint have
the that ImmTAC activating First, redirecting T is must to we cells and them tumor. the demonstrate
shown green clinical KIMMTRAK includes with ongoing some durable benefit, was for and durable over yellow, shrinkage in in shown tumor of hallmark X-year. Second, the which responses partial durable
Third, benefit reflected or parent high whether the H of we regardless the is low protein, of which the survival have patients score. expression by see gpXXX
do there uveal that we be and of for Now for KIMMTRAK early And decrease. up was and partial may of early based a melanoma note H indicates responses score. fourth, was to the XX% surrogate And at reductions on strong RECIST ctDNA higher enrichment survival. ctDNA benefit having patients an
and ultimate will the overall this all is survival, goal where ultimately course, we Of look. patients for is
accepted year. continues disease, and am more be FXXXC Beyond are dose to doses XXX,XXX later applied infectious larger ESMO the ovarian cancer in the data targets I at KIMMTRAK, be can has beyond clinical escalation we who to This PRAME, CXXXC MAGE-AX, for we is and will will efficacy this platform and as which treated patients, the update have carcinoma, oncology ImmTACs for Phase progress I month. potential The may next oral pleased has as a HIV to for by PRAME-positive, XX such evaluable. antivirals. And and our result targeting the active you The viral which reservoir update not Phase eradicated infections, that is HBV, progress I on than at X direct-acting available here. Chronic there currently patients. presentation our expansion indications. was patients. potential XX,XXX in targets
to which Our are be our achieve should We studies, platform applicable to intended be I functional and to all what reservoir called cure. eliminating MABEL including program functional Phase our HBV this doses, are of initiated subtherapeutic. cure
molecules MABEL which program, to transient we even our the in HBV a dose decrease exact in that increase the for are a find with that we biomarkers antigen, the surface However, so we on-target see potent marker of at that ALT. is disease, a expect see, HBV concomitant including
Bahija. back we only HIV have doses. initial hand microgram, small. Now a it's forward was higher pleased going functional our patient am at X announce dose, seeing achieved that remember finally, cure are happens that to to to certainly And what we look it in single this I'm But dosing after the now And I we and one to program. first below see changes and dose remarkably seen must
